Last mentioned: Feb 24, 2026
Lawsuit Announced
Rosen Law Firm announces the filing of the securities fraud class action.
Lawsuit Announced
Rosen Law Firm announces the filing of the class action lawsuit and lead plaintiff opportunity.
Appellate Loss
Teva Pharmaceuticals wins a key appeals court decision against Corcept's Korlym patents.
Teva Legal Victory
Teva Pharmaceutical Industries wins an appeals court ruling over generic versions of Corcept's Korlym.
Class Period Ends
Conclusion of the period following corrective disclosures or market events.
Class Period Ends
The cutoff date for the class action, often coinciding with a corrective disclosure.
Class Period Begins
Start of the period during which alleged misleading statements were made.
Class Period Begins
The start date for the alleged period of securities fraud and misleading statements.
Corcept Therapeutics (NASDAQ: CORT) is the target of a class action lawsuit alleging securities fraud during a critical 14-month period of operational and legal shifts. The Rosen Law Firm is seeking lead plaintiffs for a class period that concluded in late 2025, amid intensifying pressure on the company's core product patents.
Rosen Law Firm has filed a class action lawsuit against Corcept Therapeutics (NASDAQ: CORT), alleging securities fraud during a period of intense patent litigation over its flagship drug, Korlym. The lawsuit covers investors who purchased shares between October 2024 and December 2025, following significant volatility linked to generic competition threats.
Corcept Therapeutics (NASDAQ: CORT) is the target of a class action lawsuit alleging securities fraud between October 2024 and December 2025. The Rosen Law Firm is leading the litigation, which centers on claims that the company misled investors regarding its business operations and regulatory compliance. This legal challenge marks a critical period of scrutiny for the pharmaceutical firm's corporate governance and public disclosure practices.